Biospring Partners

We are a Venture Capital firm founded by leading experts in the fields of science, technology, medicine, business, and finance. We are initially focused on global medical technology. With over 40 patents and multiple successful ventures amongst the founders, we have a proven track record of astute medical and technology investment management. We don't just invest, we build, nurture and curate our community of ventures to be the best they can. We believe that with an increasing global population, an aging and ailing population in developed economies and with increases in non-communicable diseases, there exists a unique opportunity for investors to capitalise on high growth medical technology and life sciences that will not only drive high returns for investors but make the world a better place through improved quality of life.

We team with entrepreneurs to develop and commercialize technological innovations by providing capital and deep expertise in business development, market positioning, global connectivity, and operations. Anzu manages approximately $1 billion in strategic assets across three venture funds, a mezzanine revenue-based investing fund (“RBI”), and a special purpose acquisition company (“SPAC”). The venture capital funds focus on investments in early-stage companies, ranging from pre-revenue to post-commercialization, where we have deep knowledge and relationships to drive value for investors. RBI provides capital through a non-dilutive preferred share vehicle to post-revenue companies, offering an alternative to traditional venture and debt financing. Anzu Special Acquisition Corp I seeks to identify high-quality businesses with transformative technologies for industrial applications. Anzu primarily invests in companies across North America, Europe, and Asia Pacific. Founded in 2014, Anzu Partners operates a robust investment platform for industrial and life science technology companies. Anzu’s current portfolio consist of 25+ portfolio companies, and the firm has 12+ investment professionals, 260+ fund investors, and 40+ portfolio support staff. We have had several meaningful exits and manage an active pipeline of new opportunities in diligence, tracked through firm-wide pipeline reviews that cover 400-500 industrial and life science technology companies per year across the globe.

AdBio partners (formerly Advent France Biotechnology) is a venture capital firm investing in early stage life sciences companies in Europe. AdBio partners’ unique strategy combines early-stage investments in promising startups and strong entrepreneurial support to enable and strengthen the company’s growth. As an early-stage investor, we act as a catalyst to create companies based on innovations coming from academic research. We have established relationships with leading research institutions and technology transfer offices in Europe and benefit from the support of strong network of scientific, clinical, industry and financial partners. The operational team is managed by Alain Huriez, MD, Chairman and Managing Partner, and Geoffroy de Ribains, Managing Partner. The team includes seasoned investment professionals with long-standing track records in entrepreneurial ventures, combined with strong scientific, medical and operational expertise.

Empowering life science innovators to reach their full potential by providing strategic financial guidance and unlocking global investment opportunities. Your Strategic Partner for Fundraising in Life Sciences Our proven track record makes us your trusted partner for your fundraising journey 2 exits in 2024 through Gold Nest Capital - Group's asset management company USD 50 M raised in 2024 for life science companies 151 company due diligences since 2020 as investment opportunities/services 100% client satisfaction for three years running 75% requests to renew for three years running 1 biomanufacturing company founded in 2023

We back promising teams by providing both financial and business support to build the next generation of game-changing technologies companies in the field of Life Sciences. We invest in ambitious early stage start-ups and SMEs with innovative products globally, mainly across Europe and Israel. We bring strong entrepreneurial and financial expertise to portfolio companies well beyond just capital, relying on a wide network of clinicians and industry experts. We have established relationships with selected industrial partners to assist our founders in accelerating their development. We invest in people, believing that a strong and dedicated team is one of the most important factors in the success of our investments. We aim to work together with entrepreneurs to develop successful businesses as an active and well-connected investor. We invest for people, supporting the growth of companies and people that will reshape the medical world, answering real medical needs, saving lives and providing a better quality of life for patients and care-givers. An overall positive impact that will produce intrinsic value for both investors and society.

We’re not just an investor. We’re all about being an active stakeholder. Identify: We are renown for identifying early stage technologies and start-ups. Our established network and expertise enable us to do so. Incubate: We run an incubation center for our early stage start-ups that need support in early growth stage. Accelerate: We act as business development managers for our portfolio companies. We help companies collaborate in the bio-ecosystem. Funding to IPO: We back our portfolio companies in the long run. We accompany them from the very start to their success. We take entrepreneurial ideas into reality. We have been investing in the past, present and into the future. Korea to Global: Using our global pharmaceutical network we source licensing & research collaboration deals for our portfolios. Korea to China: Through collaboration with our network in China we help value up our portfolio companies. Each year we host ‘China Korea Bio Business Networking Day’ to connect Korean biotechs with Chinese pharmaceuticals and buy-side investors. Korea to Vietnam: We invest in local Vietnam start-ups and build up platforms, formulate ecosystems to accommodate the growth of future industries. And beyond… We are creators and path makers We create synergy, matrix and we take the first step for others to follow.